(PRME) Prime Medicine - Performance -25.3% in 12m
PRME performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-71.27%
#106 in Peer-Group
Rel. Strength
18.71%
#6257 in Stock-Universe
Total Return 12m
-25.32%
#91 in Peer-Group
Total Return 5y
-73.32%
#87 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 6.70 USD |
| 52 Week Low | 1.15 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 99.40 |
| Buy/Sell Signal +-5 | 1.64 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: PRME (-25.3%) vs XBI (-9.1%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
-1.02% | 69.7% | 77.8% | 23.5 | 14.1 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-10.4% | -7.09% | 151% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
2.42% | -1.57% | 39.4% | 27.2 | 14.2 | 0.99 | 0.60% | 41% |
| BIM PA Biomerieux |
-1.65% | 30.3% | -1.81% | 32.7 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
2.39% | -9.49% | -0.73% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
10.5% | 38.7% | -6.49% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-7.82% | 50.2% | -13.3% | 7.54 | 6.09 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
1.95% | 29.1% | 18.3% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: PRME vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for PRME
| Total Return (including Dividends) | PRME | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 145.51% | 0.53% | 3.75% |
| 3 Months | 256.52% | 21.37% | 25.32% |
| 12 Months | -25.32% | -9.11% | 13.11% |
| 5 Years | -73.32% | -25.99% | 109.78% |
| Trend Score (consistency of price movement) | PRME | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 90.5% | -5.7% | 80.3% |
| 3 Months | 53.5% | 79.4% | 97.2% |
| 12 Months | -90.1% | -86.9% | 45.4% |
| 5 Years | -97.2% | -52.2% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th99.00 | 144.21% | 136.63% |
| 3 Month | %th98.50 | 193.74% | 184.49% |
| 12 Month | %th54.00 | -17.83% | -33.97% |
| 5 Years | %th55.00 | -75.88% | -84.88% |
FAQs
Does Prime Medicine (PRME) outperform the market?
No,
over the last 12 months PRME made -25.32%, while its related Sector, the SPDR S&P Biotech (XBI) made -9.11%.
Over the last 3 months PRME made 256.52%, while XBI made 21.37%.
Performance Comparison PRME vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
PRME vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 49.7% | 141.8% | 24.3% | -38% |
| US NASDAQ 100 | QQQ | 49.2% | 141.3% | 22.7% | -37% |
| German DAX 40 | DAX | 47.9% | 145.3% | 11.5% | -56% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 48.7% | 141.8% | 20.6% | -47% |
| Hongkong Hang Seng | HSI | 50.2% | 142.5% | 3.8% | -64% |
| India NIFTY 50 | INDA | 50.5% | 144.7% | 23.7% | -24% |
| Brasil Bovespa | EWZ | 50.5% | 139.6% | 2.3% | -33% |
PRME vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 51.1% | 142% | 19.8% | -49% |
| Consumer Discretionary | XLY | 50.5% | 143.5% | 32.1% | -41% |
| Consumer Staples | XLP | 51% | 145.1% | 23.8% | -33% |
| Energy | XLE | 46.6% | 138.7% | 28% | -27% |
| Financial | XLF | 51% | 142.8% | 21.7% | -53% |
| Health Care | XLV | 51.5% | 144.4% | 33.2% | -20% |
| Industrial | XLI | 49.6% | 142.4% | 17.4% | -50% |
| Materials | XLB | 48.9% | 141.8% | 20.7% | -31% |
| Real Estate | XLRE | 50.9% | 145.7% | 25.4% | -37% |
| Technology | XLK | 48.1% | 138.3% | 20.2% | -35% |
| Utilities | XLU | 51.2% | 144.2% | 21.9% | -47% |
| Aerospace & Defense | XAR | 49% | 141.7% | 6.1% | -73% |
| Biotech | XBI | 48.2% | 145% | 38.4% | -16% |
| Homebuilder | XHB | 51% | 139.5% | 32.2% | -29% |
| Retail | XRT | 49.7% | 144% | 29% | -35% |
PRME vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 46.1% | 139% | 30.6% | -21% |
| Natural Gas | UNG | 52% | 156% | 43.5% | -19% |
| Gold | GLD | 51.3% | 146.3% | 6.5% | -65% |
| Silver | SLV | 48.5% | 145.8% | 8.7% | -44% |
| Copper | CPER | 43.2% | 135.4% | 3.9% | -44% |
PRME vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 52.6% | 144.4% | 28% | -22% |
| iShares High Yield Corp. Bond | HYG | 50.4% | 144.2% | 25.9% | -35% |